Protalix BioTherapeutics
PLX
PLX
31 hedge funds and large institutions have $2.45M invested in Protalix BioTherapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
56% less capital invested
Capital invested by funds: $5.61M → $2.45M (-$3.16M)
77% less call options, than puts
Call options by funds: $140K | Put options by funds: $614K
Holders
31
Holding in Top 10
–
Calls
$140K
Puts
$614K
Top Buyers
| 1 | +$427K | |
| 2 | +$113K | |
| 3 | +$89.8K | |
| 4 |
Jane Street
New York
|
+$46.8K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$42.2K |
Top Sellers
| 1 | -$1.04M | |
| 2 | -$325K | |
| 3 | -$241K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$177K |
| 5 |
Walleye Trading
New York
|
-$108K |